TY - JOUR
T1 - YB-1 als potenzielles ziel für die tumortherapie
AU - Lage, H.
AU - Surowiak, P.
AU - Holm, P. S.
PY - 2008/11
Y1 - 2008/11
N2 - The 42-kDa multifunctional cellular protein Y-box protein 1 (YB-1) is expressed in various cancers. It is localized in the cytoplasm as well as in the nucleus. In particular, YB-1 is localized in the nuclear compartment following cellular stress, such as radiation, drug treatment, hyperthermia, or viral infection. Within the nucleus, YB-1 can act as a transcription factor, and it is involved in the regulation of important cancer-associated genes. For example, YB-1 triggers the expression of Her-2 and estrogen receptor α (ERα) in breast cancer. Thus, nuclear YB-1 appears to be a potential target for the inhibition of Her-2- and ERα-dependent proliferation signals, particularly with regard to resistance to Her-2-targeting drugs such as trastuzumab. In some cancers, YB-1 may be involved in regulating MDR1/P-glycoprotein, mediating classical multidrug resistance (MDR). Furthermore, YB-1 is involved in the replication of adenovirus type 5, a commonly used vector in gene therapy. Thus, YB-1 can trigger an .,oncolytic" effect in YB-1 nuclear positive cancer cells treated with adenoviruses. Besides its impact as a prognostic factor, in the future the diagnostics of cellular YB-1 status may provide the basis for a virotherapy or a gene therapy incorporating adenoviruses.
AB - The 42-kDa multifunctional cellular protein Y-box protein 1 (YB-1) is expressed in various cancers. It is localized in the cytoplasm as well as in the nucleus. In particular, YB-1 is localized in the nuclear compartment following cellular stress, such as radiation, drug treatment, hyperthermia, or viral infection. Within the nucleus, YB-1 can act as a transcription factor, and it is involved in the regulation of important cancer-associated genes. For example, YB-1 triggers the expression of Her-2 and estrogen receptor α (ERα) in breast cancer. Thus, nuclear YB-1 appears to be a potential target for the inhibition of Her-2- and ERα-dependent proliferation signals, particularly with regard to resistance to Her-2-targeting drugs such as trastuzumab. In some cancers, YB-1 may be involved in regulating MDR1/P-glycoprotein, mediating classical multidrug resistance (MDR). Furthermore, YB-1 is involved in the replication of adenovirus type 5, a commonly used vector in gene therapy. Thus, YB-1 can trigger an .,oncolytic" effect in YB-1 nuclear positive cancer cells treated with adenoviruses. Besides its impact as a prognostic factor, in the future the diagnostics of cellular YB-1 status may provide the basis for a virotherapy or a gene therapy incorporating adenoviruses.
KW - Adenovirus
KW - Gene therapy
KW - Targeted therapy
KW - Virotherapy
KW - YB-1
UR - http://www.scopus.com/inward/record.url?scp=57449098679&partnerID=8YFLogxK
U2 - 10.1007/s00292-008-1030-2
DO - 10.1007/s00292-008-1030-2
M3 - Artikel
C2 - 18773210
AN - SCOPUS:57449098679
SN - 0172-8113
VL - 29
SP - 187
EP - 190
JO - Pathologe
JF - Pathologe
IS - SUPPL. 2
ER -